CureVac strengthens cancer vaccine research and development through the acquisition CureVac announced a collaboration with myNEO last month to look for neoantigens on the surface of tumor cells in order to develop mRNA-based cancer vaccines.
Moderna and BioNTech, and CureVac, are known as the "mRNA Troika". However, the Phase 3 clinical trial of the mRNA COVID-19 vaccine developed by CureVac failed.
CureVac has fallen far behind Moderna and BioNTech due to the failure of the...
0 Anteile
1051 Ansichten
0 Vorschau